Herbst RS, Wu YL, John T, Grohe C, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023 Jan 31:JCO2202186. doi: 10.1200/JCO.22.02186.
PMID: 36720083